港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

恆瑞醫藥

70.800

-0.300-0.42%

成交量：286.76萬

成交額：2.05億

市值：4,699.00億

市盈率：64.67

高：72.600

開：70.900

低：70.700

收：71.100

52周最高：95.200

52周最低：52.500

股本：66.37億

香港流通股本：2.58億

量比：0.77

換手率：1.11%

股息：- -

股息率：- -

每股收益(LYR):1.095

淨資產收益率：14.34%

總資產收益率：8.37%

市淨率：7.21

市盈率(LYR):64.67

市銷率: 13.85

資料載入中...

總覽公司新聞資訊公告

中國創新藥實現「造船出海」

中国产业经济信...

【信達醫藥】周觀點：Q3業績季收官，看好製藥裝備受益海外需求景氣週期

唐爱金团队研究

恆瑞、信達、百利天恆接連啓動新一期臨牀試驗

医药经济报

默沙東七赴進博會，未來五年將引進40餘新品、新適應證

南方都市报

「殺入」110億美元藍海還不夠，「醫藥一哥」又加碼

醫藥巨頭進博會「秀肌肉」：跨國藥企在華建廠、掃貨，中國創新藥年內對外授權超1000億美元

國產藥企亮相肥胖周，肥胖治療賽道迎「中國力量」

恆瑞醫藥HRS9531注射液Ⅲ期臨牀試驗數據亮相美國肥胖周大會

美元基金重新「殺」回中國創新藥！

21個藥品納入第四批鼓勵仿製藥品目錄！

「2025國談」收官！CAR-T靴子落地、AD天價藥死守價格，3圖看懂5天拉鋸戰

MedTrend医趋势

國內海風陸續開工+歐洲風電供給緊缺，這家龍頭同時佈局海洋牧場、換流站、漂浮式基礎等產品

摩尔投研精选

恆瑞醫藥HRS - 9231注射液啓動III期臨牀適應症為成人中樞神經系統外病變磁共振成像

四季度，券商建議關注醫藥主線

2025年一季度「科技金融-戰新產業指數」發佈，同環比延續漲勢

智通AH統計|11月4日

創新藥迎多重利好，券商看好投資機會

vs 重磅炸彈！恆瑞抗癌聯合療法啓動新 III 期臨牀

丁香园 Insight 数据库

創新藥ETF南方開盤跌0.41%，重倉股藥明康德跌0.43%，恆瑞醫藥漲0.03%

派格生物醫藥-B申請解散附屬公司上海邁跡；恆瑞醫藥HRS-5965膠囊擬納入優先審評｜醫藥早參

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":70.8,"timestamp":1763453299003,"preClose":71.1,"halted":0,"volume":2867625,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.0947692068187125,"marketStatus":"已收盤","change":-0.3,"latestTime":"11-18 16:08:19","open":70.9,"high":72.6,"low":70.7,"amount":205288749,"amplitude":0.026723,"askPrice":70.85,"askSize":4600,"bidPrice":70.8,"bidSize":12600,"shortable":3,"etf":0,"ttmEps":1.2701599919047246,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1763515800000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":71.1,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":0.76824,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":61.78,"timestamp":1763449200000,"preClose":61.8,"halted":0,"volume":21910000,"delay":0,"premium":"+4.68"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.37%","roe":"14.34%","lyrEps":1.094769,"volumeRatio":0.76824,"shares":6637000000,"dividePrice":0,"high":72.6,"amplitude":0.026723,"preClose":71.1,"low":70.7,"week52Low":52.5,"pbRate":"7.21","psRate":"13.85","week52High":95.2,"institutionHeld":0,"latestPrice":70.8,"committee":0.465116,"eps":1.0947692068187125,"divideRate":0,"volume":2867625,"delay":0,"ttmEps":1.2701599919047246,"open":70.9,"prevYearClose":44.05,"prevWeekClose":71.6,"prevMonthClose":75.2,"prevQuarterClose":88.8,"fiveDayClose":70.85,"twentyDayClose":79.25,"sixtyDayClose":77.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5714,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1760371200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-11-17","current":55.741009,"percent":0.292683,"low":50.027905,"twenty":52.873142,"median":57.752122,"eighty":62.273725,"high":65.582363,"avg":57.75041,"sd":4.614457,"marketCap":448676436005.11},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-17","current":54.931735,"twenty":52.873142,"median":57.752122,"eighty":62.273725,"marketCap":448676436005.11}],"updateTime":1763480047224},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581803877","title":"中國創新藥實現「造船出海」","url":"https://stock-news.laohu8.com/highlight/detail?id=2581803877","media":"中国产业经济信...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581803877?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 00:00","pubTimestamp":1762358400,"startTime":"0","endTime":"0","summary":"当前，中国创新药产业正以强劲势头融入全球医药创新体系。从十年前以仿制药为主导，到如今在全球创新药商务合作拓展交易中占比显著提升，从“跟跑”“并跑”到在部分领域“领跑”，中国创新药凭借政策支持、临床突破与资本助力，实现了从“借船出海”到“造船出海”的跨越。“截至10月份，2025年中国创新药BD交易总额已超过千亿美元，单笔交易规模屡屡刷新纪录。BD交易的持续放大，体现了全球市场对中国创新药价值的认可。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110607564194f1f085&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110607564194f1f085&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU1023057109.AUD","BK1191","09606","BK1574","LU2543165471.USD","LU0359201885.HKD","LU0359202008.SGD","06978","BK1161","01276"],"gpt_icon":0},{"id":"2581774375","title":"【信達醫藥】周觀點：Q3業績季收官，看好製藥裝備受益海外需求景氣週期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581774375","media":"唐爱金团队研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581774375?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 21:51","pubTimestamp":1762350688,"startTime":"0","endTime":"0","summary":"周观点：通过对 Q3 报的分析，创新药、CXO、医疗耗材等板块景气度相对较高。此外，自Q3起医疗器械板块已呈现业绩改善趋势。在中长期维度，我们持续推荐高景气赛道，制药装备、创新药、CXO及生命科学上游产业链、高端器械。在短期维度，我们认为可关注Q4 流感条线。制药装备受益于海外需求提升：我们跟踪到海外制药进入投资景气上行周期，建议关注森松国际、东富龙、楚天科技。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105235432a6e39d9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105235432a6e39d9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU2097828474.EUR","LU2097828805.USD","LU2097828714.EUR","02268","BK1515","LU0502904849.HKD","LU1969619763.USD","LU2097828557.USD","09887","03347","BK1191","LU2242644610.SGD","LU2097828631.EUR","02172","01066","06821","BK1583","86618","01276","BK1161","LU2488822045.USD","02315","03759","01530","LU0455707207.USD","02155","BK1589","01548","01877","00853","01477","00950","00241","LU2328871848.SGD","01801","09939"],"gpt_icon":0},{"id":"2581416727","title":"恆瑞、信達、百利天恆接連啓動新一期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2581416727","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581416727?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 20:41","pubTimestamp":1762346509,"startTime":"0","endTime":"0","summary":"01恒瑞抗癌联合疗法启动新Ⅲ期临床11月3日，药物临床试验登记与信息公示平台官网显示，恒瑞登记了一项SHR-8068联合阿得贝利单抗及含铂化疗对比度伐利尤单抗联合含铂化疗一线治疗晚期胆道癌的Ⅲ期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105204725a48aa669&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105204725a48aa669&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","01276","BK1161","LU1969619763.USD","LU2328871848.SGD","LU2097828805.USD","LU0502904849.HKD","LU2097828557.USD","LU2097828474.EUR","LU0455707207.USD","LU2488822045.USD","LU2242644610.SGD","LU2097828714.EUR","02615","BK1583","BK1589","01801"],"gpt_icon":0},{"id":"2581387560","title":"默沙東七赴進博會，未來五年將引進40餘新品、新適應證","url":"https://stock-news.laohu8.com/highlight/detail?id=2581387560","media":"南方都市报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581387560?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 19:24","pubTimestamp":1762341851,"startTime":"0","endTime":"0","summary":"在国家会展中心生物医药展馆内，默沙东第七次把“创新科学，健康未来”带上进博会——30款业已在华获批药物与疫苗集体亮相，更放出“未来五年将向中国引入40多项新产品或新适应证”的重磅信号。在其抗肿瘤板块展区内，截至2025年8月，免疫治疗产品线已在中国获批32个适应证，覆盖肺癌、胃癌等高发瘤种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105192737a6e3143f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105192737a6e3143f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU0359202008.SGD","LU0359201612.USD","LU0359201885.HKD","LU1023057109.AUD","BK1191","01276"],"gpt_icon":0},{"id":"2581387140","title":"「殺入」110億美元藍海還不夠，「醫藥一哥」又加碼","url":"https://stock-news.laohu8.com/highlight/detail?id=2581387140","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581387140?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 18:07","pubTimestamp":1762337237,"startTime":"0","endTime":"0","summary":"此次恒瑞探索瑞维鲁胺与ADC联合用药，或将开启本土新药创新在前列腺癌联合治疗领域的新阶段。本次获批临床的的是恒瑞瑞维鲁胺与HS-20093联合用药。这种“内阻外杀”的组合策略，有望克服前列腺癌的治疗耐药难题，从而进一步提升治疗效果。蓝海市场潜力待释放全球范围内，前列腺癌是男性第二大常见恶性肿瘤，2022年新发病例约146.8万例，死亡病例约39.7万例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105182613a6e2f379&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105182613a6e2f379&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359202008.SGD","01276","BK1515","BK1574","LU0359201885.HKD","BK1191","BK1161","09939","LU2543165471.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2581204742","title":"醫藥巨頭進博會「秀肌肉」：跨國藥企在華建廠、掃貨，中國創新藥年內對外授權超1000億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581204742","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581204742?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 17:32","pubTimestamp":1762335160,"startTime":"0","endTime":"0","summary":"本届进博会吸引155个国家、地区及国际组织参与，4108家境外企业参展，整体展览面积超43万平方米，规模再创新高。10月27日，安斯泰来宣布在北京设立首个中国创新研发中心。仅今年10月份，至少有8家跨国药企披露了在中国新设研发或创新中心的消息，包括礼来、辉瑞、拜耳、阿斯利康、美敦力等。医药魔方NextPharma数据库显示，截至今年10月21日，中国创新药对外授权总金额已突破1000亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110517332497557cd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110517332497557cd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999002232.USD","YINN","01276","CWEB","NVO","ASHR","BK4020","SG9999003800.SGD","BK4534","BK4533","LU1267930813.SGD","LU1430594728.SGD","LU2286300806.USD","LU0889566641.SGD","SG9999001424.SGD","IE00B19Z3581.USD","FXI","IE0002270589.USD","01801","KWEB","CSCO","LU0306806265.USD","LU0456855351.SGD","LU1023059063.AUD","BK4568","LU0985481810.HKD","LU0950375773.USD","IE00BSNM7G36.USD","IE00BFMHRM44.USD","LU0868494617.USD","CHAU","LU2506952097.USD","BK4532","CQQQ","IE00B1BXHZ80.USD","LU0823417737.USD","LU2506951958.HKD","BK4581","LU1235294995.USD","IE000M9KFDE8.USD","ASHS","BK4592","IE00BFXG1179.USD","MCHI","SG9999015952.SGD","LU0122379950.USD","SG9999002224.SGD","IE00BZ1G4Q59.USD","LU0234572021.USD","DRAG"],"gpt_icon":1},{"id":"2581038730","title":"國產藥企亮相肥胖周，肥胖治療賽道迎「中國力量」","url":"https://stock-news.laohu8.com/highlight/detail?id=2581038730","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581038730?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 11:18","pubTimestamp":1762312707,"startTime":"0","endTime":"0","summary":"2025年11月4日至7日，美国亚特兰大举办的“肥胖周”年度会议上，歌礼制药-B与恒瑞医药携重磅临床数据亮相，在这场全球肥胖治疗领域的行业盛会中，国产创新药以扎实的研究成果展现出强劲竞争力，无疑为中国创新药的国际化征程写下了浓墨重彩的一笔。两款国产新药的亮眼数据，背后是中国肥胖治疗市场的迫切需求与产业创新能力的双重驱动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105111927a4895fd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105111927a4895fd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","LU0359202008.SGD","LU2543165471.USD","LU1023057109.AUD","BK1515","01276","01672","LU0359201885.HKD","BK1191","LU0359201612.USD"],"gpt_icon":0},{"id":"2581792771","title":"恆瑞醫藥HRS9531注射液Ⅲ期臨牀試驗數據亮相美國肥胖周大會","url":"https://stock-news.laohu8.com/highlight/detail?id=2581792771","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581792771?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 08:10","pubTimestamp":1762301428,"startTime":"0","endTime":"0","summary":"格隆汇11月5日｜恒瑞医药与美国Kailera Therapeutics公司公布的GLP-1/GIP双受体激动剂HRS9531注射液Ⅲ期临床试验（GEMINI-1）数据显示，治疗48周后，HRS9531各剂量组平均减重百分比均显著优于安慰剂组，其中6 mg组平均减重19.2%。此前Ⅱ期临床试验结果显示，8 mg组平均减重23.6%。恒瑞医药已递交新药上市申请，Kailera计划年底前启动全球Ⅲ期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105081110a488f206&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105081110a488f206&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","01276","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2581794863","title":"美元基金重新「殺」回中國創新藥！","url":"https://stock-news.laohu8.com/highlight/detail?id=2581794863","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581794863?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 08:05","pubTimestamp":1762301100,"startTime":"0","endTime":"0","summary":"据悉，在恒瑞今年四笔海外BD交易中，除德国默克外，其他三个都来自于美元基金，而这刚好揭露了一个愈发明显的行业现象，即美元基金正在重新“杀”回中国创新药。由此可见，美元基金在经历过去几年的大撤退之后，如今又重新“杀”了回来，并且势头更为迅猛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105082543a488f914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105082543a488f914&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","01801","LU1969619763.USD","BK1583","LU2488822045.USD","LU0455707207.USD","ONC","BK1589","LU2097828474.EUR","LU2242644610.SGD","BK1574","LU2097828631.EUR","01877","06978","BK1161","LU2097828714.EUR","LU2097828557.USD","LU2328871848.SGD","LU0502904849.HKD","01276"],"gpt_icon":0},{"id":"2581927747","title":"21個藥品納入第四批鼓勵仿製藥品目錄！","url":"https://stock-news.laohu8.com/highlight/detail?id=2581927747","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581927747?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 07:00","pubTimestamp":1762297231,"startTime":"0","endTime":"0","summary":"10 月 28 日，国家卫健委正式发布《关于第四批鼓励仿制药品建议目录的公示》，将贝沙罗汀、地夫可特、普鲁士蓝等 21 个药品纳入其中，公示期为 5 个工作日。第四批目录的公示，进一步拓展了鼓励仿制的药品范围，其背后是对我国医疗健康领域结构性需求的精准回应。第四批鼓励仿制药品目录的推出，也将进一步推动我国仿制药行业向高质量发展转型。展望未来，鼓励仿制药品目录的动态更新将成为常态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110507003894ef7659&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110507003894ef7659&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","LU0359202008.SGD","01276","LU1023057109.AUD","LU0359201612.USD","LU2543165471.USD","BK1191","LU0359201885.HKD"],"gpt_icon":0},{"id":"2580104735","title":"「2025國談」收官！CAR-T靴子落地、AD天價藥死守價格，3圖看懂5天拉鋸戰","url":"https://stock-news.laohu8.com/highlight/detail?id=2580104735","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580104735?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 19:53","pubTimestamp":1762257181,"startTime":"0","endTime":"0","summary":"02第四天：商保谈判CAR-T“靴子”落地11月2日，商保创新药目录首日谈判开启。其中最受关注的无疑是CAR-T产品，几乎每年的国谈季，CAR-T总是无一例外地止步于初审。其余4家CAR-T目前还未传出消息，但目前面临的“形势异常危急”。此次若未能进入“商保目录”，未来这些CAR-T企业恐难以打开局面。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110420072694ee8935&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110420072694ee8935&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","JNJ","BK4532","02126","PFE","BK4007","BK4022","NVO","GILD","BK4588","IE00BZ1G4Q59.USD","BK4599","LU1093756168.USD","LU0154236417.USD","01276","BK4132","IE00BKVL7J92.USD","LU1093756325.SGD","AD","BK4230","BK4585"],"gpt_icon":1},{"id":"2580738301","title":"國內海風陸續開工+歐洲風電供給緊缺，這家龍頭同時佈局海洋牧場、換流站、漂浮式基礎等產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2580738301","media":"摩尔投研精选","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580738301?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 18:08","pubTimestamp":1762250902,"startTime":"0","endTime":"0","summary":"具体驱动力包括：国内储能迎来Q4并网高峰；国内新能源车市场因明年免购置税政策可能退坡而出现抢装；欧洲新能源车销量持续提速，9月销量同比增长33.1%；以及美国AI基建持续提速，在电力紧缺背景下带动了储能需求。目前，行业景气度持续向上。在需求持续向好的同时，行业供给端显著放缓，导致供需关系出现收紧。电池、六氟磷酸锂、磷酸铁锂、负极等环节率先迎来拐点。储能电池在Q3已陆续落地涨价，相关收益有望在Q4报表中体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104193035a6e055af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104193035a6e055af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03750","BK1116","LU1807302812.USD","LU1993786604.SGD","01276","BK1610","LU1960683339.HKD"],"gpt_icon":1},{"id":"2581631607","title":"恆瑞醫藥HRS - 9231注射液啓動III期臨牀 適應症為成人中樞神經系統外病變磁共振成像","url":"https://stock-news.laohu8.com/highlight/detail?id=2581631607","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581631607?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 18:03","pubTimestamp":1762250580,"startTime":"0","endTime":"0","summary":"本次试验主要目的为评价HRS - 9231用于身体部位磁共振成像的有效性，证明其有效性不劣于钆布醇；评价其安全性；探索受试者的群体药代动力学特征。HRS - 9231注射液为化学药物，适应症为成人中枢神经系统之外的全身其他各部位病变的磁共振成像。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104185731a6e0430d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104185731a6e0430d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","01276","LU2543165471.USD","BK1191","LU0359201885.HKD"],"gpt_icon":0},{"id":"2580478821","title":"四季度，券商建議關注醫藥主線","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478821","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580478821?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 16:30","pubTimestamp":1762245046,"startTime":"0","endTime":"0","summary":"进入四季度，A 股市场波动加剧，行业配置的确定性成为投资者关注的核心。此外，四季度医药板块还将迎来三季报披露、医保谈判等多重事件催化，业绩稳健增长、创新品种放量的企业有望获得资金青睐，进一步推动板块行情升温。展望四季度，医药板块在产业升级、政策利好、资金布局与事件催化的多重共振下，投资价值愈发凸显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104163400975300b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104163400975300b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1593","02410","BK1161","00460","BK1574","09939","06821","01276","BK1515","BK1600","06127","BK1191"],"gpt_icon":0},{"id":"2580178817","title":"2025年一季度「科技金融-戰新產業指數」發佈，同環比延續漲勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2580178817","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580178817?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 16:20","pubTimestamp":1762244455,"startTime":"0","endTime":"0","summary":"近日，由上海浦东发展银行和新华社中国经济信息社共同研发编制的“科技金融-战略性新兴产业指数”发布2025年第一季度指数结果。一季度，科技产品出口额和科研人员总数两项指标表现较为突出。表2：五大战新产业的产业成效指数同环比增速新能源汽车和新一代信息技术产业组成第一梯队。其中，新能源汽车产业成效得分206.13点，同环比增速均领跑五大行业。一季度生物产业投资未见回暖迹象，融资事件同比有所下滑，融资金额基本持平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104162206a6dfe947&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104162206a6dfe947&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HYDD.SI","LU1813983027.USD","LU1861214812.USD","LU1251922891.USD","LU0348805143.USD","LU0543330566.HKD","02359","LU0871576103.HKD","LU0289961442.SGD","LU1188198961.HKD","LU0572944931.SGD","LU2399975544.HKD","LU1719994722.HKD","LU2778985437.USD","SG9999006514.SGD","LU0259732245.USD","LU0605514214.HKD","LU0348825331.USD","LU2357125470.USD","BK1594","81211","SG9999002828.SGD","SG9999015978.USD","LU0289739343.SGD","LU1023057109.AUD","LU0531970944.HKD","LU0819123356.HKD","002594","LU0708995583.HKD","LU2294711713.HKD","SG9999006597.SGD","LU0516423091.SGD","LU0828238088.HKD","LU1808992512.USD","LU0143863198.USD","03750","BK1509","LU0540923850.HKD","LU2449936058.SGD","01211","LU0823414551.USD","SG9999015986.USD","LU1794554557.SGD","LU0214875030.USD","LU0516422440.USD","LU0516422952.EUR","LU0143863784.USD","LU0039217434.USD","01276","BYDDY","LU2506951792.HKD","LU0516423174.USD","LU0417516738.SGD"],"gpt_icon":1},{"id":"2580120099","title":"智通AH統計|11月4日","url":"https://stock-news.laohu8.com/highlight/detail?id=2580120099","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580120099?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 16:15","pubTimestamp":1762244105,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止11月4日收盘，东北电气、弘业期货、浙江世宝分列AH溢价率前三位，溢价率分别为900.00%、258.42%、252.00%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-17.17%、1.22%、5.23%。其中东北电气、长飞光纤光缆、山东墨龙的偏离值位居前三，分别为64.66%、27.92%、27.79%；另外，中海油田服务、昊海生物科技、中国东方航空股份的偏离值位居后三，分别为-12.36%、-9.36%、-9.08%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01988","00107","02899","LU0640798160.USD","01812","BK1183","03678","00038","02338","BK1522","00670","01349","BK1530","02883","03968","00358","00187","LU0326950275.SGD","01330","02880","06869","02648","00300","01276","03606","03143","BK1144","LU2097828631.EUR","SG9999004220.SGD","01108","02465","IE00BZ08YT58.USD","00042","00553","LU1794554557.SGD","01033","01071","02359","LU0417516571.SGD","01919","06826","00568","01057","159982","02218","399300","03750"],"gpt_icon":1},{"id":"2580678149","title":"創新藥迎多重利好，券商看好投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2580678149","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580678149?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 15:49","pubTimestamp":1762242586,"startTime":"0","endTime":"0","summary":"在全球医药产业格局重塑与国内政策红利持续释放的双重背景下，中国创新药产业正迎来新的发展机遇期。券商机构普遍看好这一赛道的投资价值，其中国金证券明确指出，创新药主线及左侧板块困境反转将是2025-2026年医药板块的最大投资机会。当前，全链条创新优势凸显、国际化进程加速、政策精准赋能的多重利好共振，正推动中国创新药从“跟跑”向“并跑”“领跑”跨越，医疗行业也由此站上新的发展起点，即将开启新一轮增长浪潮。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110415514094ee0d68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110415514094ee0d68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01276","BK1574","BK1161","09606","06978","02591","02552"],"gpt_icon":0},{"id":"2581763193","title":"vs 重磅炸彈！恆瑞抗癌聯合療法啓動新 III 期臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2581763193","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581763193?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 15:28","pubTimestamp":1762241285,"startTime":"0","endTime":"0","summary":"11 月 3 日，药物临床试验登记与信息公示平台官网显示，恒瑞登记了一项SHR-8068 联合阿得贝利单抗及含铂化疗对比度伐利尤单抗联合含铂化疗一线治疗晚期胆道癌的 III 期临床研究。阿得贝利单抗注射液是恒瑞自主研发的人源化抗 PD-L1 单克隆抗体，已于 2023 年获批上市，获批适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。2024 年全球销售额达 47.17 亿美元，同比增长 11.33%，为阿斯利康 14 款重磅炸弹中收入前三的产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104155803a6dfdac1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104155803a6dfdac1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD","LU1023057109.AUD","01276","BK1191","LU0359202008.SGD"],"gpt_icon":1},{"id":"2580127431","title":"創新藥ETF南方開盤跌0.41%，重倉股藥明康德跌0.43%，恆瑞醫藥漲0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580127431","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580127431?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 09:36","pubTimestamp":1762220160,"startTime":"0","endTime":"0","summary":"11月4日，创新药ETF南方（159858）开盘跌0.41%，报0.724元。其重仓股表现各异，药明康德跌0.43%，恒瑞医药涨0.03%，长春高新跌0.15%，科伦药业、复星医药涨幅为0，华东医药跌0.14%，百济神州跌0.42%，信立泰跌0.33%，康龙化成跌1.02%，百利天恒涨0.49%。该ETF业绩比较基准为中证创新药产业指数收益率，由南方基金管理股份有限公司管理，基金经理朱恒红，自2021年3月12日成立以来回报为-27.45%，近一个月回报为-5.47%。市场有风险，投资需谨慎，本文信息仅作参考，不构成个人投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104095124a6df1c88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104095124a6df1c88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","LU0052750758.USD","LU0708995583.HKD","01276","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2125910500.SGD","BK1141","LU2543165471.USD","BK1191","LU0320764599.SGD","BK1583","LU0359201612.USD","LU2242644610.SGD","BK1576","02359","LU2045819591.USD"],"gpt_icon":0},{"id":"2580229492","title":"派格生物醫藥-B申請解散附屬公司上海邁跡；恆瑞醫藥HRS-5965膠囊擬納入優先審評｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2580229492","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580229492?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 07:14","pubTimestamp":1762211657,"startTime":"0","endTime":"0","summary":"｜2025年11月4日星期二｜NO.1派格生物医药申请自愿解散非全资附属公司上海迈迹派格生物医药-B宣布，公司已于2025年10月28日申请自愿解散公司的非全资附属公司上海迈迹生物医药科技有限公司（以下简称“上海迈迹”）。上海迈迹是一家于2017年6月26日成立的有限责任公司，从事GLP-2（一种参与肠道功能及代谢的肽类激素）的研究及开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511043553895263.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511043553895263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023057109.AUD","LU2543165471.USD","02565","BK1161","LU0359201885.HKD","BK1191","BK1515","BK1574","LU0359201612.USD","09939","01276","LU0359202008.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}